How to CGRP receptor?

Novel therapeutic agents for the treatment of migraine,Constrained compounds as CGRP-receptor antagonists,Calcitonin gene related peptide receptor antagonists,CGRP receptor antagonists,Constrained compounds as CGRP-receptor antagonists

CGRP receptor patented technology retrieval search results - Eureka

Novel therapeutic agents for the treatment of migraine

ActiveUS20050215576A1Good effectBiocideNervous disorderCGRP receptorObstructive Pulmonary Diseases

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Novel therapeutic agents for the treatment of migraine

View all

Owner:BRISTOL MYERS SQUIBB CO

Constrained compounds as CGRP-receptor antagonists

ActiveUS20060094707A1BiocideNervous disorderCGRP receptorHeadaches

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Constrained compounds as CGRP-receptor antagonists

View all

Owner:BRISTOL MYERS SQUIBB CO

Calcitonin gene related peptide receptor antagonists

InactiveCN1671711ACompounds screening/testingCompound screeningCGRP receptorNK1 receptor antagonist

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Calcitonin gene related peptide receptor antagonists

View all

Owner:BRISTOL MYERS SQUIBB CO

CGRP receptor antagonists

ActiveUS8314117B2BiocideNervous disorderCGRP receptorHeadaches

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

View all

Owner:BRISTOL MYERS SQUIBB CO

Constrained compounds as CGRP-receptor antagonists

ActiveUS7384930B2BiocideNervous disorderCGRP receptorNK1 receptor antagonist

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt

ActiveUS20130225636A1BiocideNervous disorderDiseaseCGRP receptor

Disclosed is a hemisulfate salt of Compound (I):and crystalline forms of the hemisulfate salt. Also disclosed are methods of using the hemisulfate salt of Compound (I) as a CGRP receptor antagonist, and pharmaceutical compositions comprising the hemisulfate salt of Compound (I). The hemisulfate salt of Compound (I) is useful in treating, preventing, or ameliorating disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt

View all

Owner:BRISTOL MYERS SQUIBB CO

Heterocyclic anti-migraine agents

ActiveUS20050153959A1Good effectBiocideNervous disorderCGRP receptorObstructive Pulmonary Diseases

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

Spirocyclic Anti-migraine compounds

ActiveUS20070149502A1Compounds screening/testingBiocideCGRP receptorObstructive Pulmonary Diseases

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

Heterocyclic anti-migraine agents

ActiveUS7569578B2BiocideOrganic active ingredientsCGRP receptorObstructive Pulmonary Diseases

The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

CGRP antagonists

ActiveUS20070049577A1BiocideOrganic chemistryCGRP receptorObstructive Pulmonary Diseases

The present invention encompasses compounds of Formula I which are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

Anti-migraine spirocycles

ActiveUS7842808B2Compounds screening/testingCompound screeningCGRP receptorHeadaches

The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

Methods for treating or preventing migraine headache

ActiveUS20160311913A1Efficient reductionPrevent and reduce occurrenceNervous disorderAutomatic syringesRegimenCGRP receptor

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

Methods for treating or preventing migraine headache

View all

Owner:AMGEN INC

Therapeutic agents for the treatment of migraine

ActiveUS7772244B2BiocideNervous disorderCGRP receptorHeadaches

The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Therapeutic agents for the treatment of migraine

View all

Owner:BRISTOL MYERS SQUIBB CO

Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof

ActiveUS20060122250A1BiocideOrganic active ingredientsCGRP receptorStereochemistry

The invention relates to novel processes for the preparation of small molecule antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”) and intermediates thereof.

Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof

View all

Owner:BRISTOL MYERS SQUIBB CO

CGRP receptor antagonist

ActiveUS8481546B2Organic active ingredientsNervous disorderCGRP receptorObstructive Pulmonary Diseases

The disclosure generally relates to the compound of formula I, (R)—N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, including pharmaceutically acceptable salts, which is a CGRP-receptor antagonist. The disclosure also relates to pharmaceutical compositions and methods for using the compound in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cancer.

View all

Owner:BRISTOL MYERS SQUIBB CO

Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods

InactiveUS7193070B2FungiBacteriaCGRP receptorMammal

Disclosed herein are isolated nucleic acid molecules encoding a humanized version of a calcitonin gene-related peptide (CGRP) receptor, which comprises the G-protein coupled receptor calcitonin-receptor-like receptor (CRLR) and the receptor-activity-modifying protein 1 (RAMP1). The humanized CGRP receptors of the present invention attain pharmacological profiles similar to the wild type human receptor via modifications to the respective mammalian RAMP1 nucleotide sequence, specifically at amino acid 74. Also described are related recombinant vectors, recombinant hosts and associated methods for generating such humanized CGRP receptors. Also presented are non-human transgenic animals which express humanized RAMP1. Such animals have been engineered to provide for a CGRP pharmacological profile similar to human CGRP.

Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods

View all

Owner:MERCK SHARP & DOHME CORP +1

CGRP Receptor Antagonists

ActiveUS20110251223A1BiocideNervous disorderCGRP receptorObstructive Pulmonary Diseases

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

View all

Owner:BRISTOL MYERS SQUIBB CO

CGRP receptor antagonists

ActiveUS8044043B2BiocideNervous disorderDiseaseCGRP receptor

The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

View all

Owner:BRISTOL MYERS SQUIBB CO

Method of treating migraine headaches using calcitonin gene related peptide mimetics

InactiveUS20050222158A1BiocideAnimal repellantsCGRP receptorMedicine

Methods of treating migraine comprising conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides are disclosed. The compounds of the present invention of Formula I have valuable pharmacological properties based on their ability to selectively antagonize calcitonin gene-related peptide (CGRP) receptor for acute and prophylactic treatment of headaches, particularly migraines.

Method of treating migraine headaches using calcitonin gene related peptide mimetics

View all

Owner:BRISTOL MYERS SQUIBB CO

Constrained compounds as cgrp-receptor antagonists

ActiveCN101495480ANervous disorderOrganic chemistryCGRP receptorNK1 receptor antagonist

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

Constrained compounds as CGRP-receptor antagonists

ActiveUS7384931B2BiocideNervous disorderCGRP receptorNK1 receptor antagonist

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors

View all

Owner:BRISTOL MYERS SQUIBB CO

CGRP Receptor Antagonists

ActiveUS20090258866A1BiocideNervous disorderThermal injuryCGRP receptor

The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

View all

Owner:BRISTOL MYERS SQUIBB CO

N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt

ActiveUS8759372B2BiocideNervous disorderObstructive Pulmonary DiseasesHeadaches

Disclosed is a hemisulfate salt of Compound (I):and crystalline forms of the hemisulfate salt. Also disclosed are methods of using the hemisulfate salt of Compound (I) as a CGRP receptor antagonist, and pharmaceutical compositions comprising the hemisulfate salt of Compound (I). The hemisulfate salt of Compound (I) is useful in treating, preventing, or ameliorating disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt

View all

Owner:BRISTOL MYERS SQUIBB CO

CGRP antagonists

ActiveUS7834007B2BiocideOrganic chemistryDiseaseCGRP receptor

The present invention encompasses compounds of Formula Iwhich are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

View all

Owner:BRISTOL MYERS SQUIBB CO

Methods for treating or preventing migraine headache

ActiveUS10259877B2Efficient reductionPrevent and reduce occurrenceNervous disorderAutomatic syringesCGRP receptorRegimen

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

View all

Owner:AMGEN INC

CGRP receptor antagonists

ActiveUS9808457B2Organic active ingredientsSenses disorderCGRP receptorMedicine

The disclosures herein relate to novel compounds of formulawherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

View all

Owner:HEPTARES THERAPEUTICS

Processes for the preparation of CGRP-receptor antagonists and intermediates thereof

ActiveUS7449586B2Organic active ingredientsBiocideCGRP receptorNK1 receptor antagonist

The invention relates to novel processes for the preparation of small molecule antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”) and intermediates thereof.

Processes for the preparation of CGRP-receptor antagonists and intermediates thereof

View all

Owner:BRISTOL MYERS SQUIBB CO

Constrained compounds as cgrp-receptor antagonists

ActiveUS20070259851A1BiocideNervous disorderDiseaseCGRP receptor

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.